What did @clareelisabeth actually say?
She started Zepbound (tirzepatide) and reported almost no immediate side effects the first evening. By morning, she described feeling "kind of hungover" with a mild headache and some queasiness that seemed to worsen the more she thought about it. She was honest that she was not sure whether the medication had even kicked in yet, saying "I don't think it's kicked in yet for sure."
She also mentioned going to the gym the next morning, drinking a protein shake, and eating hard-boiled eggs, framing high protein intake as an intentional strategy. Her comparison to IVF medications in the caption suggests she has a high tolerance baseline for injectable drugs, which is relevant context for how she interpreted her experience.
Does the science back this up?
Yes, broadly. The delayed and mild onset she described is consistent with tirzepatide's pharmacokinetics. A hangover-like feeling on day one is plausible and under-discussed in official prescribing information, but the mechanism makes sense.
Tirzepatide is a dual GIP and GLP-1 receptor agonist with a half-life of approximately five days. After a single 2.5 mg starter dose, peak plasma concentration occurs around 8 to 72 hours post-injection, which means most people feel the drug most acutely in the 24 to 48 hour window after their first shot (Frías et al., 2021, New England Journal of Medicine). The mild nausea and headache she described track with the most commonly reported adverse events in the SURMOUNT-1 trial, where nausea occurred in roughly 28 percent of tirzepatide patients versus 9 percent on placebo (Jastreboff et al., 2022, New England Journal of Medicine). A general feeling of malaise or fatigue in the first 24 hours is not a documented clinical endpoint, but it is consistent with the body adjusting to a new GLP-1 pathway stimulus.
What did they get wrong (or right)?
She got more right than wrong here. Her instinct to eat protein, stay active, and not catastrophize mild symptoms is genuinely reasonable advice that aligns with what clinicians suggest.
Where she was slightly off: she said "I don't think it's kicked in yet" while simultaneously describing textbook early GLP-1 side effects. The drug almost certainly was beginning to act on her system. Onset of nausea and appetite suppression can start within hours of the first dose for some patients, even at the 2.5 mg starter dose. Her lack of appetite that morning was likely at least partially medication-driven, not purely her baseline eating pattern. She undersells this connection, though it is a minor point and she was not making a strong claim either way.
Her observation that thinking about nausea made it worse is also clinically interesting. Anticipatory nausea is a real phenomenon documented in chemotherapy patients (Roscoe et al., 2011, Supportive Care in Cancer) and her live self-awareness of this was more medically sophisticated than she probably realized.
What should you actually know?
The "hungover" feeling after a first GLP-1 injection is more common than clinical trial language suggests, and it tends to be worst with the first one or two doses before the body adapts. It usually improves significantly by week three or four as patients titrate up gradually.
A few things worth knowing if you are starting tirzepatide:
- The 2.5 mg starter dose exists specifically to minimize early side effects. Going slower is not weakness, it is the design of the drug.
- Protein intake matters. GLP-1 medications can suppress appetite enough that muscle loss becomes a real risk if people are not intentional about hitting protein targets. Her instinct here was correct. Research from Wilding et al. (2021, New England Journal of Medicine) on semaglutide noted that roughly 40 percent of weight lost included lean mass without dietary intervention.
- Headache and fatigue on day one can also reflect mild dehydration if food and fluid intake dropped after the shot. That is a simple fix.
- If nausea persists beyond the first few days or becomes severe, that is worth contacting a prescriber about, not just pushing through.
One more thing: her IVF comparison in the caption is doing a lot of work. Prior experience with injectable hormones that cause real, significant side effects probably does raise a person's baseline tolerance. That context matters for how she interprets her experience, but it does not mean everyone starting Zepbound will have it this easy.